Canada Prostate Cancer Hormone Therapy Market Size, Share & Industry Analysis, By Drug Class (Gonadotropin Releasing Hormone Agonist {By Product Type [Lupron, Eligard, & Zoladex], By Route of Administration [Oral and Parenteral]}, Gonadotropin-Releasing Hormone Receptor Antagonist {By Product Type [FIRMAGON, ORGOVYX, & Others], By Route of Administration [Oral & Parenteral], Androgen Receptor Inhibitors [Oral & Parenteral], and Others, By Disease State (Metastatic Castration-Resistant Prostate Cancer, & Others), By Distribution Channel, and Regional Forecast, 2025-2032

Last Updated: December 24, 2025 | Format: PDF | Report ID: FBI114940

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2024
Forecast Period	2025-2032
Historical Period	2019-2023
Growth Rate	CAGR of 5.60% from 2025-2032
Unit	Value (USD Million)
Segmentation	By Drug Class, Disease State, and Distribution Channel
By Drug Class	Gonadotropin Releasing Hormone (GnRH) Agonist By Product Type Lupron Eligard Zoladex Others By Route of Administration Oral Parenteral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist By Product Type FIRMAGON ORGOVYX Others By Route of Administration Oral Parenteral Androgen Receptor Inhibitors Oral Parenteral Others Oral Parenteral
By Disease State	Metastatic Castration-Resistant Prostate Cancer Non-Metastatic Castration-Resistant Prostate Cancer Others
By Distribution Channel	Hospital Pharmacies Drug Stores & Retail Pharmacies Online Pharmacies